ADMEDUS grew revenue by 58% last year FY17
NEO and vascucel are growing fast off a small base.
The 3D curved patch needs time to fall into the mainstream.
Expectations are on ADAPT doing about $3M.
INFUSION lets say $3.5M.
This seems to be a general idea.
NOW ADMEDUS in FY17 had revenue of about $6M DOLLARS
in its first Qtr.
So if ADMEDUS is growing at say 20% pa. shoudnt revenue be
$1.2M more in FY18. making the total $7.2M.
DYOR
ADMEDUS grew revenue by 58% last year FY17 NEO and vascucel are...
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.13 |
Change
-0.220(1.20%) |
Mkt cap ! $352.7M | |||
| Open | High | Low | Value | Volume |
| $18.36 | $18.47 | $18.13 | $30.26K | 1.664K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 12 | $18.13 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.35 | 48 | 2 |
View Market Depth
| Last trade - 10.32am 03/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |